Monday, September 23, 2013
Geron, a Menlo Park, Calif.-based biopharmaceutical company developing first-in-class therapies for cancer, has discontinued development of GRN1005, its peptide-drug conjugate designed to treat cancers in the brain. Going forward, the company will focus on the development of imetelstat, its telomerase inhibitor, in hematologic myeloid malignancies and in patients with solid tumors that have short telomeres.
GlaxoSmithKline has extended its tender offer to acquire all of the outstanding shares of Human Genome Sciences for $13.00 per share in cash to 5:00 p.m. EST on Friday, June 29, 2012. The tender offer was previously scheduled to expire at 12:00 midnight EST, at the end of the day on June 7, 2012.